Insights

Gathering insights about Inventiva…

Similar companies to Inventiva

Inventiva Tech Stack

Inventiva uses 5 technology products and services including Google Hosted Libraries, Google Font API, jQuery, and more. Explore Inventiva's tech stack below.

Google Hosted Libraries
Content Delivery Network
Google Font API
Font Scripts
jQuery
Javascript Libraries
Webflow
Page Builders
reCAPTCHA
Security

Media & News

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California.
Dec 17, 2024 | www.globenewswire.com
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that, following the general meeting of the shareholders held on December 11, 2024 (the “General Meeting”), the Board of Directors decided to use the delegations granted by the General Meeting to issue the second phase of Tranche 1 (the “T1 bis Transaction”) for a gross amount of €21.4 million (net amount of €20.1 million) of the multi-tranche equity financing of up to €348 million announced on October 14, 2024 (the “Multi-Tranche Financing”).
Dec 16, 2024 | www.globenewswire.com
Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders' Meeting.
Dec 12, 2024 | www.globenewswire.com
Inventiva reports 2024 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024.
Nov 21, 2024 | www.globenewswire.com
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of December 11, 2024.
Nov 20, 2024 | www.globenewswire.com
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Nov 18, 2024 | www.businesswire.com
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in San Diego California.
Nov 15, 2024 | www.globenewswire.com

Inventiva's Email Address Formats

Inventiva uses at least 1 format(s):

Inventiva Email Formats	Example	Percentage
LFirst@inventiva.com	DJohn@inventiva.com	29%
First@inventiva.com	John@inventiva.com	28%
FLast@inventiva.com	JDoe@inventiva.com	14%
LFirst@inventiva.com	DJohn@inventiva.com	29%

Frequently Asked Questions

Where is Inventiva's headquarters located?

Inventiva's main headquarters is located at Austin, TX 78701 US. The company has employees across 4 continents, including South AmericaNorth AmericaAsia.

What is Inventiva's phone number?

You can contact Inventiva's main corporate office by phone at

+1-830-438-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Inventiva's stock symbol?

Inventiva is a publicly traded company; the company's stock symbol is IVA.

What is Inventiva's official website and social media links?

Inventiva's official website is inventiva.com and has social profiles on LinkedIn.

How much revenue does Inventiva generate?

As of May 2024, Inventiva's annual revenue reached $3.8M.

What is Inventiva's SIC code NAICS code?

Inventiva's SIC code is 8742 - Management Consulting Services NAICS code is 541810 - Advertising Agencies.

How many employees does Inventiva have currently?

As of May 2024, Inventiva has approximately 44 employees across 4 continents, including South AmericaNorth AmericaAsia. Key team members include Owner: N. C.Executive Vice President: M. K.Creative Services Director: E. G.. Explore Inventiva's employee directory with LeadIQ.

What industry does Inventiva belong to?

Inventiva operates in the Advertising Services industry.

What technology does Inventiva use?

Inventiva's tech stack includes Google Hosted LibrariesGoogle Font APIjQueryWebflowreCAPTCHA.

What is Inventiva's email format?

Inventiva's email format typically follows the pattern of . Find more Inventiva email formats with LeadIQ.

When was Inventiva founded?

Inventiva was founded in 1990.

Inventiva

Advertising ServicesTexas, United States11-50 Employees

Award winning multicultural marketing, advertising and consulting firm.

Company Overview

Headquarters: Austin, TX 78701 US
Phone number: +1-830-438-****
Website: inventiva.com
SIC Code: 8742 - Management Consulting Services
Stock Symbol: IVA
NAICS Code: 541810 - Advertising Agencies
Founded: 1990
Employees: 11-50

Media & News

Funding & Financials

$10M
Inventiva's revenue is in the range of $10M

Funding & Financials

$10M
Inventiva's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Inventiva

Medpace

Charles River Laboratories

Syneos Health

Covance

IQVIA

WuXi AppTec

Labcorp Drug Development

Spero Therapeutics

Parexel

Inventiva Tech Stack

Media & News

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Inventiva reports 2024 Third Quarter Financial Information¹

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Inventiva's Email Address Formats

Frequently Asked Questions

Where is Inventiva's headquarters located?

What is Inventiva's phone number?

What is Inventiva's stock symbol?

What is Inventiva's official website and social media links?

How much revenue does Inventiva generate?

What is Inventiva's SIC code NAICS code?

How many employees does Inventiva have currently?

What industry does Inventiva belong to?

What technology does Inventiva use?

What is Inventiva's email format?

When was Inventiva founded?

Inventiva

Company Overview

Media & News

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?